Immunogenicity of a 26-valent group A streptococcal vaccine. - Wikidata - awgldk - TriplyDB

Immunogenicity of a 26-valent group A streptococcal vaccine.

Immunogenicity of a 26-valent group A streptococcal vaccine.

http://www.wikidata.org/entity/Q34121015

about

Multilocus sequence typing of Streptococcus pyogenes representing most known emm types and distinctions among subpopulation genetic structures Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge Accelerating the development of a group A Streptococcus vaccine: an urgent public health need Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus Anti-Group A Streptococcal Vaccine Epitope: STRUCTURE, STABILITY, AND ITS ABILITY TO INTERACT WITH HLA CLASS II MOLECULES Epidemiology of Invasive Group A Streptococcal Disease in Alaska, 2001 to 2013.The worldwide epidemiology of acute rheumatic fever and rheumatic heart disease.Relationships between emm and multilocus sequence types within a global collection of Streptococcus pyogenes.National Department of Defense surveillance data for antibiotic resistance and emm gene types of clinical group A streptococcal isolates from eight basic training military sites Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.Identification and molecular characterisation of a fibrinogen binding protein from Streptococcus iniae.Streptococcus iniae M-like protein contributes to virulence in fish and is a target for live attenuated vaccine development Comparative analysis of emm type pattern of Group A Streptococcus throat and skin isolates from India and their association with closely related SIC, a streptococcal virulence factor Group A streptococcal genotypes from throat and skin isolates in the United Arab Emirates Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens.Factors associated with Group A Streptococcus emm type diversification in a large urban setting in Brazil: a cross-sectional study.Identity and prevalence of multilocus sequence typing-defined clones of group A streptococci within a hospital setting Higher rates of streptococcal colonization among children in the Pacific Rim Region correlates with higher rates of group A streptococcal disease and sequelae The NH(2)-terminal region of Streptococcus pyogenes M5 protein confers protection against degradation by proteases and enhances mucosal colonization of mice.Six-month multicenter study on invasive infections due to Streptococcus pyogenes and Streptococcus dysgalactiae subsp. equisimilis in Argentina.Invasive group A streptococcal infection in older adults in long-term care facilities and the community, United States, 1998-2003 Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes.Streptococcal emm types in Hawaii: a region with high incidence of acute rheumatic fever.M protein gene (emm type) analysis of group A beta-hemolytic streptococci from Ethiopia reveals unique patterns.Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections.Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structure-activity relationship Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils.Molecular epidemiologic comparison of 2 unusual clusters of group a streptococcal necrotizing fasciitis in Hawaii.Disease manifestations and pathogenic mechanisms of Group A Streptococcus.Nationwide laboratory-based surveillance of invasive beta-haemolytic streptococci in Denmark from 2005 to 2011.Group A streptococcus expresses a trio of surface proteins containing protective epitopes.Inactivated and live, attenuated influenza vaccines protect mice against influenza: Streptococcus pyogenes super-infections.Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens.Seven-year surveillance of emm types of pediatric Group A streptococcal pharyngitis isolates in Western Greece.Genes, autoimmunity and pathogenesis of rheumatic heart disease.Evaluation of emm gene types, toxin gene profiles and clonal relatedness of group A streptococci New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci Invasive group A streptococcal infections, clinical manifestations and their predictors, Montreal, 1995-2001.Group A Streptococcus emm gene types in pharyngeal isolates, Ontario, Canada, 2002-2010.

P2860

Q24564671-C8727D7A-7615-446F-AF92-CE6687C49481 Q24657762-2C6DBD6E-FD9F-4785-B067-9B99917B9853 Q26739210-C9C9DBAF-C3CC-469E-839F-6FA6714A4976 Q27009175-A01C2DBD-AA49-4D92-8B76-738BF582A734 Q27666345-F75157DD-10F3-43A6-823F-CC90B3276933 Q30202103-28887B2B-1765-43F4-AC9A-6B21E659E640 Q30432965-748D8F93-5A48-4436-976D-78DBB3579226 Q30481807-EE94CE6D-C87B-4974-BE3D-DF8F26CCBBC3 Q30881760-80B66074-FC8C-43B8-821B-B63B7AE83C33 Q33253260-D6AEC196-B1FE-4395-938D-F05ECAF1EB25 Q33330200-F8D78AF5-27C9-4A77-BDDF-9BBD1A83BD34 Q33355994-98BA65C3-AF7D-41C4-B8F8-A6B1D1E2BD2D Q33369963-0D18F7F5-7D36-4B8E-9DCD-9EE99EB6FC16 Q33549923-F248A5A0-A9E5-4D4F-9DF3-85E2910C6D2B Q33719415-65CB429A-0D94-4B5B-BE76-0405093ACD23 Q33744547-320A547A-579A-4ECB-9DC9-58B24EBAC9D3 Q33753390-24D09556-3AC9-46F2-B9F4-D0BE2E01F059 Q33794061-0E6DAFB8-0154-47D4-A3DA-E83904A0B27E Q33804050-59BB88AB-A8C1-4E6B-97C5-D0DA25E71194 Q33824679-FE4CE78A-FE29-4599-8D2B-EA1ACE17A073 Q33877781-F9B74BFF-4EF4-4BF4-810C-08E679258B55 Q33910815-878D80BC-32A8-42FA-A86A-36FB51968810 Q34005434-83480869-194A-47BE-8AB8-4F652B34BFE7 Q34036156-0EFAE6BE-DE8E-485B-AAFE-AB2C941696DC Q34042270-494B6884-C150-4F1C-AFC9-421F44AA4AE2 Q34112608-00002CC5-724C-4E5C-A384-513531CC589D Q34131142-FE6D62BA-925E-404C-A272-EEE266B133C2 Q34194488-4B66D2CB-04C8-4029-8ABF-56FF42BC15AA Q34345145-0830E1F3-F270-4CF5-9ACA-4FF2DFB91F42 Q34413457-6B958360-B607-4F3B-8C0A-B5C022E957BE Q34511201-DBC03FA0-9486-44F0-90DF-A66D94F5716A Q34701389-B3C2EFCD-AF18-435D-B18E-7EC40CE66E57 Q34885060-218BEDE4-9201-4BF1-934F-35FD57073ECD Q34934867-D4C75F17-8B45-4130-ADD6-019BD78828C0 Q34971503-5932114F-4A86-4974-809F-18D7CDE53FA4 Q35015039-666F93A6-E098-480C-BDFB-BA09352B95A0 Q35099922-5467E39E-CEBC-4F80-96C5-5FFD30B533DB Q35376757-4E6E40CE-5142-4DE1-B4B3-9B80653BC59D Q35804371-C5F91FF5-9075-4422-8F22-5040CE88CE6E Q35847191-F1258FE3-886E-40BD-9F8B-44B632BF70DB

P2860

Immunogenicity of a 26-valent group A streptococcal vaccine.

http://www.wikidata.org/entity/Q34121015

description

2002 nî lūn-bûn

@nan

2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Immunogenicity of a 26-valent group A streptococcal vaccine.

@ast

Immunogenicity of a 26-valent group A streptococcal vaccine.

@en

Immunogenicity of a 26-valent group A streptococcal vaccine.

@nl

type

label

Immunogenicity of a 26-valent group A streptococcal vaccine.

@ast

Immunogenicity of a 26-valent group A streptococcal vaccine.

@en

Immunogenicity of a 26-valent group A streptococcal vaccine.

@nl

prefLabel

Immunogenicity of a 26-valent group A streptococcal vaccine.

@ast

Immunogenicity of a 26-valent group A streptococcal vaccine.

@en

Immunogenicity of a 26-valent group A streptococcal vaccine.

@nl

P1433

Q34121015-97751565-C89D-46A2-95A2-D4BBE60D1B2F

P1476

Q34121015-4896CE81-A6C9-4FE9-B126-39CF7FD6408C

P2093

Q34121015-1076D4A3-E32E-4343-B664-102FEFE2D322

Q34121015-49068225-6EB9-45E4-9084-29253847E277

Q34121015-76C46235-9EB1-4CA3-B384-D16C63514F43

Q34121015-8D52F056-73E8-49C8-A809-14809A08C031

Q34121015-F5189029-C122-4720-AD7E-3C4A8D041744

P2860

Q34121015-04B727F3-FDD2-479B-8851-593374962E57

Q34121015-0702E364-1714-4370-9E04-B921F7321F1E

Q34121015-18CCA7B1-4E7F-4504-B55E-7EBFD9790FD5

Q34121015-29CDD4EE-46B5-436A-A9FF-74C57F78B3FE

Q34121015-29F7CE2A-4B5B-4604-855C-9B016932C9CA

Q34121015-357ABB28-8C5D-4DF6-BA64-3EA1EBF2BC72

Q34121015-3E2DF322-999C-4BA0-BAAB-3D2F6CD461B0

Q34121015-424C6317-EAB7-4BAD-AAD1-40067AE41424

Q34121015-5E700B14-73A5-4BD0-ABB0-C92389A3238D

Q34121015-60E8DF5F-73BC-47B4-8651-30649B4C863C

P304

Q34121015-5BE76D77-4E56-43D2-B01A-BD2209637918

P31

Q34121015-1582A29E-46BD-4212-A8DD-0D3809E8BA71

P356

Q34121015-573A96B1-EA56-454C-AF9B-B9BAEEF3FAB9

P407

Q34121015-19907914-588F-469C-BF90-6128CD20DDB9

P433

Q34121015-7A36559F-4D41-4E19-AE84-1E70D644EB4D

P478

Q34121015-AB365CCA-FA1D-4D15-B730-CCABFDCC752D

P50

Q34121015-9B7EE345-4543-4966-B98E-30882C324F55

P577

Q34121015-CECEBEFA-9D9D-473E-87B2-A892D8AB4BC9

P698

Q34121015-BC7DF2BC-9B9C-468D-8C0C-97E2A705F327

P932

Q34121015-89AB11B9-5BE6-4C4B-92BD-18825A58710E

P356

IAI.70.4.2171-2177.2002

P1433

Infection and Immunity

P1476

Immunogenicity of a 26-valent group A streptococcal vaccine

@en

P2093

Bernard Beall

http://www.w3.org/2001/XMLSchema#string

Mark A Reddish

http://www.w3.org/2001/XMLSchema#string

Mary C Hu

http://www.w3.org/2001/XMLSchema#string

Michael A Walls

http://www.w3.org/2001/XMLSchema#string

Steven D Stroop

http://www.w3.org/2001/XMLSchema#string

P2860

Pathogenesis of group A streptococcal infections

Active bacterial core surveillance of the emerging infections program network.

The flesh-eating bacterium: what's next?

New protective antigen of group A streptococci.

Persistence of type-specific antibodies in man following infection with group A streptococci

Current knowledge of type-specific M antigens of group A streptococci.

Spa contributes to the virulence of type 18 group A streptococci.

STUDIES ON THE BIOLOGY OF STREPTOCOCCUS : I. ANTIGENIC RELATIONSHIPS BETWEEN STRAINS OF STREPTOCOCCUS HAEMOLYTICUS

Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci.

Streptococcal M6 protein expressed in Escherichia coli. Localization, purification, and comparison with streptococcal-derived M protein

P304

2171-2177

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/IAI.70.4.2171-2177.2002

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11895984

http://www.w3.org/2001/XMLSchema#string

P932

127884

http://www.w3.org/2001/XMLSchema#string